Osteonecrosis of the jaw is a severe disease that poses a higher risk to patients receiving bisphosphonate therapy. This review endeavors to determine the link between dental implant patients receiving BP therapy and the risk of ONJ.

1. Osseointegration of Dental Implants NYC in Patients Undergoing
Bisphosphonate Treatment
Osteonecrosis of the jaw is a severe disease that poses a higher risk to patients receiving
bisphosphonate therapy. This review endeavors to determine the link between dental implant
patients receiving BP therapy and the risk of ONJ.
Dental Implants NYC and the Risk of Osteonecrosis Induced by Bisphosphonate
Treatment: Study Motivation
Bisphosphonates (BPs) are an important group of drugs used for the treatment of metabolic and
oncologic (cancer-related) pathologies involving the skeletal system. However, osteonecrosis
of the jaw (ONJ) is a complication observed in patients using oral or intravenous (IV) BPs.
Osteonecrosis, from its Latin origins, can literally be translated to “Bone death” and occurs when
the bone loses its blood supply, resulting in structural collapse and incredible pain and arthritis.
In the case of ONJ, the bone of the mandible and/or maxilla can be affected by this severe
diseasing causing the appearance of lesions in the gingiva (gums) that do not heal. Furthermore,
acute infection, inflammation and pain set in as the bone, which is exposed by the lesions,
deteriorates.
Investigating the Link Between Dental Implants NYC and the Risk of Osteonecrosis in
Patients Receiving BP Therapy
As a result of the observations connecting patients undergoing BP therapy and ONJ, those who
are expected to receive dental implants NYC should be informed of the possible risks. The
purpose of this particular literature review is to assess the osseointegration of dental implants
NYC in patients undergoing BP therapy. Osseointegration refers to the biological fusing
of the titanium screws of the dental implants NYC to the bone of the jaw. The MEDLINE-
PubMed databases of The National Library of Medicine, National Institutes of Health, Bethesda,
Maryland, were searched for articles addressing the focused question: Can dental implants
NYC osseointegrate and remain functionally stable in patients undergoing oral and IV BP
therapy? In other words, could dental implants NYC be successful in patients receiving BP
therapy intravenously? To begin finding the answer to this core research issue, databases were
searched from 1995 up to and including February 2010 using the following terms in different
combinations:
● Bisphosphonate,
● Dental implant,
● Immediate-loading,
● Implant survival rate,
● Intravenous,
● Oral,
● Osseointegration, and
● Osteonecrosis.

2. Dental Implants NYC, BP Therapy and ONJ: Review Results
The initial search of the above-mentioned keywords yielded 89 articles. Scrutiny of the titles and
abstracts reduced the number of articles to 12 (seven case reports and five retrospective studies).
In 10 studies, the patients were using oral BPs, and in two studies, patients were using IV BPs.
The results of the review were as follows:
● Six case reports showed that the placement of dental implants NYC in patients using BPs
could yield a successful osseointegration and post-operative function.
● Four retrospective studies demonstrated that BPs did not have a negative influence on
implant success.
● Two studies showed a negative impact of BPs on implant success.
Of the 12 case studies performed, only two demonstrated that BP had a negative impact upon the
success of dental implants NYC. In conclusion, the authors remark that dental implants NYC can
biologically fuse with the jaw bone (osseointegrate) and remain functionally stable in patients
using BPs.